

PERSONAL INFORMATION **Marco Tuccori**WORK EXPERIENCE

- August 2009- Present **Pharmacovigilance Head, Adverse Drug Reaction Monitoring Unit**
University Hospital of Pisa (Italy)
Member of the Directory of the Tuscan Regional Centre for Pharmacovigilance
Member of the Committee for the Signal Detection Analysis, Italian Agency on Drugs (Agenzia Italiana del Farmaco, AIFA), Italian Ministry of Health, Rome

EDUCATION AND TRAINING

- 1995- 2001 **graduation in pharmacy (PharmD)**
University of Pisa, school of pharmacy (Italy)
- 2002- 2005 **Pharmacology specialist**
Postgraduate School of Pharmacology, University of Pisa (Italy)
- 2009- 2011 **PhD in Pharmacology and Medical Pathophysiology**
University of Pisa (Italy)
- 2005- 2005 **Master in Clinical Investigation and Drug Development**
University of Pisa (Italy)
Division of Pharmacology and Chemotherapy, Department of Internal Medicine
- 2008- 2008 **Intensive Course in Epidemiology and Medical Statistics**
London School of Hygiene and Tropical Medicine (United Kingdom)
- 2009- 2009 **Master in Pharmacovigilance**
University of Florence (Italy)
- 2010- 2010 **Eudravigilance User Training Course Certificate**
European Medicinal Agency (EMA), London (United Kingdom)
- 2015- 2015 **Post-Doctoral Fellowship at the Centre for Clinical Epidemiology**
Jewish General Hospital, McGill University (Montreal) (Canada)

ADDITIONAL INFORMATION

- Expertise **Pharmacovigilance**
Drug safety
Pharmacotherapy

Publications Peer Reviewed Journal

1. Focosi D, Tuccori M, Antonelli G, Maggi F. What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? *Clin Microbiol Infect.* 2020 Sep 29:S1198-743X(20)30589-9. doi: 10.1016/j.cmi.2020.09.036. Online ahead of print.
2. Convertino I, Lucenteforte E, Gini R, Lorenzoni V, Cazzato M, Turchetti G, Trieste L, Ferraro S, Leonardi L, Roberto G, Luciano N, Blandizzi C, Mosca M, Tuccori M. Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons. *Clin Exp Rheumatol.* 2020 Aug 5. Online ahead of print.
3. Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent Plasma Therapy for COVID-19: State of the Art. *Clin Microbiol Rev.* 2020 Aug 12;33(4):e00072-20. doi: 10.1128/CMR.00072-20. Print 2020 Sep 16
4. Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, Blandizzi C. The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. *Drug Saf.* 2020 Aug;43(8):699-709. doi: 10.1007/s40264-020-00965-w.
5. Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. *Crit Care.* 2020 Jun 11;24(1):331. doi: 10.1186/s13054-020-03020-3.
6. Furlan G, Caduff-Janosa P, Sottosanti L, Cappello E, Valdiserra G, Tuccori M. Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward. *Drug Saf* (2020). doi:10.1007/s40264-020-00949-w
7. Lombardi N, Crescioli G, Bettiol A, Tuccori M, Capuano A, Bonaiuti R, Mugelli A, Venegoni M, Vighi GD, Vannacci A; MEREAFaPS Study group. Italian Emergency Department Visits and Hospitalizations for Outpatients' Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study) *Front Pharmacol.* 2020 Apr 6;11:412. doi: 10.3389/fphar.2020.00412. eCollection 2020.
8. Focosi D, Tuccori M, Maggi F. Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes? *Ann Transl Med.* 2019 Dec;7(Suppl 8):S298. doi: 10.21037/atm.2019.11.07.
9. Ferraro S, Convertino I, Leonardi L, Blandizzi C, Tuccori M. Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance. *Expert Opin Drug Saf.* 2019 Oct 3. doi: 10.1080/14740338.2019.1676724. [Epub ahead of print]
10. Lombardi N, Crescioli G, Bettiol A, Tuccori M, Rossi M, Bonaiuti R, Ravaldi C, Levi M, Mugelli A, Ricci S, Lippi F, Azzari C, Bonanni P, Vannacci A. Predictors of vaccines safety in children and in general population: 1-year pharmacovigilance study on adverse events following immunization. *Front Pharmacol* 2019 (accepted, in press)
11. Kirchmayer U, Narduzzi S, Mayer F, Tuccori M, Leoni O, Belleudi V, Di Martino M, Lallo A, Addis A, Davoli M. [Sicurezza ed efficacia nella reale pratica clinica dei nuovi anticoagulanti orali versus gli antagonisti della vitamina K: risultati di uno studio in 3 regioni italiane.] *Recenti Prog Med.* 2019 Apr;110(4):195-202. doi: 10.1701/3154.31345.
12. Ferraro S, Leonardi L, Convertino I, Blandizzi C, Tuccori M. Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. *Front Pharmacol.* 2019 Mar 19;10:247. doi: 10.3389/fphar.2019.00247. eCollection 2019.
13. Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From

- Disproportionality Analysis of the FDA Adverse Event Reporting System. *Target Oncol.* 2019 Apr;14(2):205-221. doi: 10.1007/s11523-019-00632-w.
14. Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. *Drug Saf.* 2018 Dec 18. doi: 10.1007/s40264-018-0768-6.
15. Convertino I, Ferraro S, Blandizzi C, Tuccori M. The usefulness of listening social media for Pharmacovigilance purposes: a systematic review. *Expert Opin Drug Saf.* 2018 Nov;17(11):1081-1093. doi: 10.1080/14740338.2018.1531847. Epub 2018 Oct 12.
16. Convertino I, Salvadori S, Pecori A, Galiulo MT, Ferraro S, Parrilli M, Corona T, Turchetti G, Blandizzi C, Tuccori M. Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis. *Drug Saf.* 2018 Oct 1. doi: 10.1007/s40264-018-0737-0. [Epub ahead of print]
17. Tuccori M, Convertino I, Galiulo MT, Marino A, Capogrosso-Sansone A, Blandizzi C. Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. *Expert Opin Drug Saf.* 2017 Oct;16(10):1133-1148. doi: 10.1080/14740338.2017.1361401. Epub 2017 Aug 4.
18. Capogrosso Sansone A, Covertino I, Galiulo MT, Salvadori S, Pieroni S, Knazevic T, Mantarro S, Marino A, Hauben M, Blandizzi C, Tuccori M. Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. *Drug Safety* 2017 [Epub ahead of print]
19. Pasqualetti G, Calsolaro V, Bini G, Dell'Agnello U, Tuccori M, Marino A, Capogrosso-Sansone A, Rafanelli M, Santini M, Orsitto E, Ungar A, Blandizzi C, Monzani F. Clinical differences among the elderly admitted to the emergency department for accidental or unexplained falls and syncope. *Clin Interv Aging.* 2017 Apr 13;12:687-695. doi: 10.2147/CIA.S127824.
20. Bigi C, Tuccori M, Bocci G. Healthcare professionals and pharmacovigilance of pediatric adverse drug reactions: a 5-year analysis of Adverse Events Reporting System database of the Food and Drug Administration. *Minerva Pediatr.* 2017 Feb 17. doi: 10.23736/S0026-4946.17.04733-8. [Epub ahead of print]
21. Bate A, Beckmann J, Doodoo A, Härmark L, Hartigan-Go K, Hegerius A, Lindquist M, van Puijenbroek E, Tuccori M, Hagemann U. Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery. *Drug Saf.* 2017 Mar;40(3):191-199. doi: 10.1007/s40264-016-0495-9
22. Lapi F, Capogrosso Sansone A, Mantarro S, Simonetti M, Tuccori M, Blandizzi C, Rossi A, Corti G, Bartoloni A, Bellia A, Baiocchi L, Cricelli I, Cricelli C. Hepatitis C virus infection: opportunities for an earlier detection in primary care. *Eur J Gastroenterol Hepatol.* 2017 Mar;29(3):271-276. doi: 10.1097/MEG.0000000000000785
23. Marino A, Capogrosso-Sansone A, Tuccori M, Bini G, Calsolaro V, Mantarro S, Convertino I, Pasqualetti G, Orsitto E, Santini M, Monzani F, Blandizzi C. Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study. *Expert Opin Drug Saf.* 2016 Dec;15(sup2):45-50
24. Convertino I, Capogrosso Sansone A, Marino A, Galiulo MT, Mantarro S, Antonioli L, Fornai M, Blandizzi C, Tuccori M. Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. *Drug Saf.* 2016 Oct;39(10):903-24
25. Tuccori M, Fillion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. *BMJ.* 2016 Mar 30;352:i1541.
26. Tuccori M, Blandizzi C. SSRIs and birth defects: can a new statistical approach resolve old controversies? *Evidence-Based Mental Health.* 2016 Aug;19(3):e19.
27. Montagnani S, Tuccori M, Testi A, Cristofano M, Corona T, Salvadori S, Scarpignato C, Blandizzi C. Adherence with regulatory resolutions on prevention of NSAIDs-related gastrointestinal injury in Italy. *Int J Clin Pharm.* 2016 Aug;38(4):829-37.]
28. Tuccori M, Fillion KB, Azoulay L. RE: Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome. *JNCI* 2016, 108(2): x-xi
29. Tuccori M, Wu JW, Yin H, Majdan A, Azoulay L. The Use of Glyburide Compared With Other

- Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes. *Diabetes Care*. 2015 Nov;38(11):2083-9. doi: 10.2337/dc15-1358. Epub 2015 Sep 4.
30. Capogrosso Sansone A, Mantarro S, Tuccori M, Ruggiero E, Montagnani S, Convertino I, Marino A, Fornai M, Antonioli L, Corona T, Garibaldi D, Blandizzi C. Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. *Drug Saf*. 2015 Oct;38(10):869-88. doi: 10.1007/s40264-015-0336-2.
31. Martinucci I, Blandizzi C, de Bortoli N, Bellini M, Antonioli L, Tuccori M, Fornai M, Marchi S, Colucci R. Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. *Pharmacogenomics*. 2015 Apr;16(5):523-39. doi: 10.2217/pgs.15.12.
32. Mantarro S, Capogrosso-Sansone A, Tuccori M, Blandizzi C, Montagnani S, Convertino I, Antonioli L, Fornai M, Cricelli I, Pecchioli S, Cricelli C, Lapi F. Allopurinol adherence among patients with gout: an Italian general practice database study. *Int J Clin Pract*. 2015 Jul;69(7):757-65. doi: 10.1111/ijcp.12604. Epub 2015 Feb 16.
33. Antonioli L, Giron MC, Colucci R, Pellegrini C, Sacco D, Caputi V, Orso G, Tuccori M, Scarpignato C, Blandizzi C, Fornai M. Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats. *PLoS One*. 2014 Dec 30;9(12):e116253.
34. Carnovale C, Brusadelli T, Zuccotti G, Beretta S, Sullo MG, Capuano A, Rossi F, Moschini M, Mugelli A, Vannacci A, Laterza M, Clementi E, Radice S; MEAP Group (Acampora L, Acquaviva A, Albano R, Aliberti F, Antoniazzi S, Azzari C, Berni R, Bertella S, Besana R, Biassoni V, Blandizzi C, Borali E, Borin F, Borsadoli C, Boschiero A, Bussolini A, Bottone R, Carissimi A, Casnaghi D, Casullo C, Cattaneo S, Cherubini S, Chielli A, Colombo RR, Cometti M, Conio S, Corradino M, Cusmai R, De Giacomo C, De Rosa S, Della Giovanna M, Di Benedetto D, Di Maggio G, Dovera E, Femiano P, Figini C, Fiori AM, Galbiati G, Gari S, Gentili M, Locati C, Lombardi N, Lusck R, Maggini V, Magni E, Martelli A, Masiello S, Merlo M, Molteni M, Moltoni D, Montrasio G, Muserra G, Nisic A, Panzeri F, Parilli M, Parolo E, Peroni D, Perrone V, Pettini R, Pianaroli A, Poggi V, Pomo V, Pozzi M, Primavera A, Pugi A, Punginelli M, Re B, Riva E, Rivolta S, Roman B, Rondonani G, Rosco A, Rossi M, Ruggeri I, Salvati D, Salvini F, Sanmartino G, Siani P, Speziali A, Spoldi L, Stabile S, Sterpa A, Tonella M, Tosi A, Tozzi P, Tuccori M, De Pava MV, Vecchio S, Vighi G, Viri M, Vitale A, Giovanni VR, Zonca S, Zuliani C, Pellegrino P). The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy. *Expert Opin Drug Saf*. 2014 Sep;13 Suppl 1:S1-8. doi: 10.1517/14740338.2014.928692.
35. Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M, Blandizzi C. Adverse reaction to oncologic drugs: spontaneous reporting and signal detection. *Expert Rev Clin Pharmacol* 2015 Jan;8(1):61-75.
36. Beckmann J, Hagemann U, Bahri P, Bate A, Boyd IW, Dal Pan GJ, Edwards BD, Edwards IR, Hartigan-Go K, Lindquist M, McEwen J, Moride Y, Olsson S, Pal SN, Soulaymani-Bencheikh R, Tuccori M, Vaca CP, Wong IC. Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum. *Drug Saf*. 2014 Aug 30.
37. Tuccori M, Montagnani S, Mantarro S, Capogrosso-Sansone A, Ruggiero E, Saporiti A, Antonioli L, Fornai M, Blandizzi C. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. *CNS Drugs*. 2014 Mar;28(3):249-72. doi: 10.1007/s40263-013-0135-1.
38. Antonioli L, Fornai M, Awwad O, Giustarini G, Pellegrini C, Tuccori M, Caputi V, Qesari M, Castagliuolo I, Brun P, Giron MC, Scarpignato C, Blandizzi C, Colucci R. Role of the A2B receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rat. *Br J Pharmacol*. 2014 Mar;171(5):1314-29. doi: 10.1111/bph.12539.
39. Fornai M, Antonioli L, Colucci R, Pellegrini C, Giustarini G, Testai L, Martelli A, Matarangasi A, Natale G, Calderone V, Scarpignato C, Tuccori M, Blandizzi C. NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? *J Pharmacol Exp Ther*. 2014 Jan;348(1):86-95. doi: 10.1124/jpet.113.207118.
40. Pugi A, Bonaiuti R, Maggini V, Moschini M, Tuccori M, Leone R, Rossi M, Motola D, Piccinni C, Ferrazin F, Sottosanti L, Mugelli A, Vannacci A, Lapi F. Safety profile of antiviral medications: A pharmacovigilance study using the Italian spontaneous-reporting database. *Am J Health Syst*

Pharm. 2013 Jun 15;70(12):1039-1046.

41. Tuccori M, Giustarini G, Blandizzi C, Capogrosso-Sansone A, Rossi M, Gori G, Scarpini F, Mantarro S, Montagnani S, Vannacci A, Antonioli L, Fornai M, Lapi F. Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. *Journal of Public Health (Germany)* 21 (4) , pp. 365-372
42. Antonioli L, Colucci R, Pellegrini C, Giustarini G, Tuccori M, Blandizzi C, Fornai M. The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. *Pharmacol Ther.* 2013 Aug;139(2):157-88. doi: 10.1016/j.pharmthera.2013.04.002.
43. Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magné N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. *Oncotarget.* 2013 Apr;4(4):502-30.
44. Colucci R, Gambaccini D, Ghisu N, Rossi G, Costa F, Tuccori M, De Bortoli N, Fornai M, Antonioli L, Ricchiuti A, Mumolo MG, Marchi S, Blandizzi C, Bellini M. Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. *PLoS One.* 2013;8(2):e54831. doi: 10.1371/journal.pone.0054831. Epub 2013 Feb 5
45. Mantarro S, Tuccori M, Pasqualetti G, Tognini S, Montagnani S, Monzani F, Blandizzi C. Acute portal vein thrombosis precipitated by indomethacin in a HCV-positive elderly patient. *BMC Geriatr.* 2012 Nov 13;12:69. doi: 10.1186/1471-2318-12-69.
46. Manganelli S, Rossi M, Tuccori M, Galeazzi M. Guillain-Barré syndrome following adalimumab treatment. *Clin Exp Rheumatol.* 2012 Jul-Aug;30(4):592
47. Colucci R, Antonioli L, Bernardini N, Ippolito C, Segnani C, Awwad O, Tuccori M, Blandizzi C, Scarpignato C, Fornai M. Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing. *J Pharmacol Exp Ther.* 2012 Jul;342(1):140-9
48. Tuccori M, Pisani C, Bachini L, Pardini M, Mantarro S, Antonioli L, Fornai M, Rubinelli M, Cirinei C, Blandizzi C. Telogen effluvium following bivalent human papilloma virus vaccine administration: a report of two cases. *Dermatology.* 2012;224(3):212-4.
49. Antonioli L, Colucci R, La Motta C, Tuccori M, Awwad O, Da Settimo F, Blandizzi C, Fornai M. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. *Curr Drug Targets.* 2012 Jun;13(6):842-62.
50. Lazzeri D, Agostini T, Bocci G, Giannotti G, Fanelli G, Naccarato AG, Danesi R, Tuccori M, Pantaloni M, D'Aniello C. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. *Clin Breast Cancer.* 2011 Oct;11(5):283-96.
51. Antonioli L, Fornai M, Colucci R, Tuccori M, Blandizzi C. A holistic view of adenosine pathways in the control of intestinal neuromuscular functions: the enteric purinome concept. *Br J Pharmacol.* 2011 Nov;164(6):1577-9.
52. Tuccori M, Lapi F, Testi A, Ruggiero E, Moretti U, Vannacci A, Bonaiuti R, Antonioli L, Fornai M, Giustarini G, Scollo C, Corona T, Ferrazin F, Sottosanti L, Blandizzi C. Drug-induced taste and smell alterations: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. *Drug Saf.* 2011 Oct 1;34(10):849-59.
53. Antonioli L, Fornai M, Colucci R, Tuccori M, Blandizzi C. Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics? *Expert Opin Investig Drugs.* 2011 Jun;20(6):717-21. doi: 10.1517/13543784.2011.579104.
54. Cristiani C, Tuccori M, Pepe P, Sarteschi A, Maddalo F, Simonini G, Michi P, Consigli V, Fornai M, Antonioli L, Blandizzi C. Safety of MF-59 adjuvanted vaccine for pandemic influenza: Results of the vaccination campaign in an Italian health district. *Vaccine.* 2011 Apr 18;29(18):3443-8.
55. Fornai M, Colucci R, Antonioli L, Awwad O, Ugolini C, Tuccori M, Fulceri F, Natale G, Basolo F, Blandizzi C. Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug

- (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: characterization of molecular mechanisms. *Pharmacol Res.* 2011 Jan;63(1):59-67.
56. Montagnani S, Tuccori M, Lombardo G, Testi A, Mantarro S, Ruggiero E, Blandizzi C. Autoimmune haemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. *Ann Pharmacother.* 2011 Jan;45(1):e8.
57. Gori G, Spinelli G, Spinelli C, Tuccori M, Blandizzi C, Del Tacca M. Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia. *Nat Rev Gastroenterol Hepatol* 2010 Nov;7(11):642-6.
58. Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, Pistello M, Antonioli L, Fornai M, Pepe P, Rossi G, Petrini M. Inclusion of rituximab in treatment protocols for non-Hodgkin lymphomas and the risk of progressive multifocal leukoencephalopathy. *Oncologist* 2010;15(11):1214-9.
59. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Awwad O, Bin A, Zoppellaro C, Castagliuolo I, Gaion RM, Giron MC, Blandizzi C. Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. *Br J Pharmacol.* 2010 Oct;161(4):856-71.
60. Tuccori M, Montagnani S, Testi A, Ruggiero E, Mantarro S, Scollo C, Pergola A, Fornai M; Antonioli L; Colucci R, Corona T; Blandizzi C. Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Major and Cardiovascular Malformations: An Update. *Postgraduate Med* 2010 Jul;122(4):49-65.
61. Antonioli L, Fornai M, Colucci R, Awwad O, Ghisu N, Tuccori M, Da Settimo F, La Motta C, Natale G, Duranti E, Viridis A, Blandizzi C. The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. *J Pharmacol Exp Ther.* 2010 Nov;335(2):434-42. doi: 10.1124/jpet.110.171223.
62. Focosi D, Tuccori M, Kast RE, Maggi F, Ceccherini-Nelli L, Petrini M. Progressive multifocal leukoencephalopathy: whats new? *Neuroscientist* 2010;16:308-323
63. Lapi F, Tuccori M, Motola D, Pugi A, Vietri M, Montanaro M, Vaccheri M, Leoni O, Cocci A, Leone R, Conforti A, Moretti U, Sessa E, Mazzaglia G, Mazzei T, Mugelli A, Vannacci A. Fluoroquinolones Safety Profile: Analysis of Adverse Drug Reactions in Relation to Prescription Data. An Italian pharmacovigilance study using four regional databases. *Drug Safety Drug Saf.* 2010 Sep 1;33(9):789-99.
64. Tuccori M, Guidi B, Montagnani S, Fornai M, Antonioli L, Blandizzi C, Di Paolo M. Transient acute liver failure complicating transurethral resection (TUR) syndrome: a case report. *Scand J Urol Nephrol* 2010 Sep;44(4):269-72
65. Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A. Data mining of spontaneous reporting database as a tool to identify adverse drug reactions associated with drug-drug interactions. *Drug Saf.* 2010 Aug 1;33(8):667-75
66. Fornai M, Antonioli L, Colucci R, Berardini N, Ghisu N, Tuccori M, De Giorgio R, Del Tacca M, Blandizzi C. Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. *Pharmacol Ther.* 2010;125:62-78
67. Tuccori M, Focosi D, Maggi F, Cosottini M, Meini B, Lena F, Blandizzi C, Del Tacca M, Petrini M. Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkins lymphomas treated with rituximab. *Ann Hematol* 2010;89(5):519-523.
68. Tuccori M, Focosi D, Blandizzi C, Del Tacca M, Petrini M. Re: "Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials" *J Natl Cancer Inst.* 2009;101(18):1288-1289
69. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, Colucci R, Corona T, Blandizzi C, Del Tacca M. Safety concerns associated with the use of serotonin reuptake and other serotonergic/noradrenergic antidepressants during pregnancy: a review. *Clin Ther* 2009;31(mental health theme issue),1426-1453.
70. Colucci R, Fornai M, Antonioli L, Ghisu N, Tuccori M, Blandizzi C, Del Tacca M. Characterization of mechanisms underlying the effects of esomeprazole on the impairment of gastric ulcer healing with addition of NSAID treatment. *Dig Liver Dis.* 2009 Jun;41(6):395-405.

71. Blandizzi C, Tuccori M, Colucci R, Fornai M, Antonioli L, Narcisa G, Del Tacca M. Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. *Pharmacol Res* 2009 Feb;59(2):90-100.
72. Fornai M, Antonioli L, Colucci R, Ghisu N, Bucciante P, Marioni A, Chiarugi M, Tuccori M, Blandizzi C, Del Tacca M. A(1) and A(2a) receptors mediate inhibitory effects of adenosine on the motor activity of human colon. *Neurogastroenterol Motil.* 2009 Apr;21(4):451-66.
73. Fornai M, Colucci R, Antonioli L, Ghisu N, Tuccori M, Blandizzi C, Del Tacca M. Effects of pantoprazole on ulcer healing delay associated with NSAID treatment. *Naunyn Schmiedebergs Arch Pharmacol.* 2009 Mar;379(3):305-13.
74. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, Blandizzi C. Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. *Pharmacol Ther* 2008 Dec;120(3):233-53.
75. Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, Motola D, Salvo F, Rivolta AL, Blandizzi C, Mugelli A, Del Tacca M. Statin-associated psychiatric adverse events: a case/non case evaluation of an Italian database of spontaneous adverse drug reaction reporting. *Drug Saf* 2008;31(12):1115-23
76. Fornai M, Colucci R, Antonioli L, Ghisu N, Tuccori M, Gori G, Blandizzi C, Del Tacca M. Effects of a bicarbonate-alkaline water on digestive motility in experimental models of functional gastrointestinal disorders. *Methods Find Exp Clin Pharmacol* 2008 May;30(4):261-9
77. Salvo F, Polimeni G, Cutroneo PM, Leone R, Conforti A, Moretti U, Motola D, Tuccori M, Caputi AP. Allergic reactions to oral drugs: a case/non-case study from an Italian spontaneous reporting database (GIF). *Pharmacol Res.* 2008 Sep-Oct;58(3-4):202-7.
78. Tuccori M, Guidi B, Carulli G, Blandizzi C, Del Tacca M, Di Paolo M. Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome. *Platelets* 2008 Aug;19(5):384-7
79. Lattanzi L, Danesi R, Lastella M, Mungai F, Di Paolo A, Tuccori M, Cassano GB, Del Tacca M. Serotonin syndrome and the T102 C polymorphism of the 5-HT_{2A} receptor: a case report. *Bipolar Disorders* 2008 Jul;10(5):655-6
80. Tuccori M, Bresci F, Guidi B, Blandizzi C, Del Tacca M, Di Paolo M. Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis: a case report with review of literature. *Ann Pharmacother* 2008 Jul;42(7):1112-7
81. Blandizzi C, Tuccori M, Colucci R, Gori G, Fornai M, Antonioli L, Ghisu N, Del Tacca M. Clinical efficacy of esomeprazole in the prevention and healing of digestive toxicity associated with non-steroidal anti-inflammatory drugs in elderly patients. *Drugs Aging* 2008;25(3):197-208
82. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, Blandizzi C. Pharmacological Modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. *Inflamm Bowel Dis* 2008;14(4):566-74
83. Blandizzi C, Fornai M, Colucci R, Antonioli L, Crema F, Bucciante P, Chiarugi M, Baschiera F, Ghisu N, Tuccori M, Del Tacca M. CCK2 receptors mediate inhibitory actions of cholecystokinin on the contractile activity of human distal colon via the nitric oxide pathway. *Br J Pharmacol* 2007 Aug;151(8):1246-53
84. Tuccori M, Lombardo G, Lapi F, Vannacci A, Blandizzi C, Del Tacca M. Gabapentin-induced severe myopathy. *Ann Pharmacother.* 2007 Jul;41(7):1301-5
85. Fornai M, Colucci R, Antonioli L, Baschiera F, Ghisu N, Tuccori M, Gori G, Blandizzi C, Del Tacca M. CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon. *Eur J Pharmacol* 2007 Feb 28;557(2-3):212-20
86. Colucci R, Fornai M, Tuccori M, Antonioli L, Pasqualetti G, Blandizzi C, Del Tacca M. Tolerability profiles of leukotriene receptor antagonists and long-acting 2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma. A review. *J Asthma* 2007 Jul-Aug;44(6):411-22
87. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M. Reply to the Letter to the Editor on 'Cost-opportunity analysis in clinical oncology: from the "wild far-west" to a correct integration of the disciplines, avoiding the "war of the worlds", by D. Tassinari et al. (*Ann Oncol* 2006; 17: 876) *Ann Onc* 2006 May 1;17(5):877-8

88. Tuccori M, Giovannoni S, Giustizi SE, Blandizzi C, Del Tacca M. Acute severe myopathy following single intravenous infusion of omeprazole. *Ann Pharmacother* 2006 Feb;40(2):352-3
89. Tuccori M, Martini G, Giustizi SE, Salvetti A, Blandizzi C, Del Tacca M. Haemorrhagic gastritis and bleeding following rofecoxib administration. *Clin Exp Rheum.* 2005 Sep-Oct;23:727-8
90. Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antonioli L, Baldi S, Lubrano V, Abramo A, Blandizzi C, Del Tacca M. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2005 Jul;372:79-87
91. Bocci G, Tuccori M, Emmenegger U, Liguori V, Kerbel RS, Del Tacca M. Cyclophosphamide-methotrexate metronomic chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation of novel chemotherapy strategies. *Ann Oncol* 2005 Aug;16(8):1243-52
92. Franceschi A, Tuccori M, Bocci G, Di Paolo A, Vannozzi F, Barbara C, Lastella M, Blandizzi C, Del Tacca M. Drug therapeutic failure in emergency department patients. A university hospital experience. *Pharmacol Res* 2004 Jan;49(1):85-91

Books and book chapters

1. Tuccori M, Walberg M. Other Source of Information for Monitoring Drug Safety. Now and in the Future in Edwards IR, Lindquist M *Pharmacovigilance* Ed Springer International Publishing, Switzerland, 2016
2. Fornai M, Antonioli L, Colucci R, Tuccori M, Blandizzi C. Pathophysiology of Gastric Ulcer Development and Healing: Molecular Mechanisms and Novel Therapeutic Options. In *Peptic Ulcer Disease*, ED. Intech, Rijeka (Croatia), 2011
3. Del Tacca M, Tuccori M. Reazioni avverse ematologiche. In: Caputi AP, De Ponti F, Pagliaro L. *Reazioni avverse ai farmaci: sospetto e diagnosi*. Raffaello Cortina Editore, Milano, 2009
4. Danesi R, Tuccori M, Del Tacca M. Farmaci antineoplastici anticorpi citotossici in: Rossi F, Cuomo V, Riccardi C. *Farmacologia Principi di base e applicazioni terapeutiche*. Edizioni Minerva Medica, Torino, 2005 Seconda edizione 2016
5. Franceschi A, Tuccori M. Tollerabilità renale Effetti sulla pressione arteriosa in: M Del Tacca *Farmacologia preclinica e clinica degli inibitori selettivi di ciclo-ossigenasi-2*. Pacini Editore, Pisa, 2004
6. Tuccori M. Profilo di tollerabilità generale e interazioni farmacodinamiche in: Del Tacca M *Farmacologia preclinica e clinica degli inibitori selettivi di ciclo-ossigenasi-2*. Pacini Editore, Pisa, 2004

Projects

Memberships

- Member of the International Society of Pharmacovigilance (ISoP) since October 2004
- Coordinator of the ISoP Italian Chapter since 2012
- Member of the Executive Committee of the International Society of Pharmacovigilance (ISoP) (2012-2016)
- Member of the Advisory Board of the International Society of Pharmacovigilance (ISoP) (2017-2019)
- Member of the International Society of PharmacoEpidemiology (ISPE) since August 2019
- Member of the Italian Society of Pharmacology (SIF) since June 2005
- Chair of the Local Organizing Committee of the 13th Annual World Meeting of the International Society of Pharmacovigilance, Pisa October 1st - 4th, 2013

Other Relevant Information

- Educational grants Study grants for Pharmacovigilance from the Italian Society of Pharmacology (SIF) (July 2002 to November 2004)
- Fellowships for Pharmacovigilance issued by the Interdepartmental Centre for Research in Clinical Pharmacology and Experimental Therapeutics, University of Pisa (December 2004-June 2009)